Grifols SA, Barcelona (NASDAQ: GRFS) and Trillium Therapeutics (NASDAQ:TRIL) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, dividends, risk, analyst recommendations, valuation and institutional ownership.
Earnings & Valuation
This table compares Grifols SA, Barcelona and Trillium Therapeutics’ top-line revenue, earnings per share and valuation.
||Earnings Per Share
|Grifols SA, Barcelona
Grifols SA, Barcelona has higher revenue and earnings than Trillium Therapeutics. Trillium Therapeutics is trading at a lower price-to-earnings ratio than Grifols SA, Barcelona, indicating that it is currently the more affordable of the two stocks.
This is a breakdown of current ratings and price targets for Grifols SA, Barcelona and Trillium Therapeutics, as reported by MarketBeat.com.
||Strong Buy Ratings
|Grifols SA, Barcelona
Trillium Therapeutics has a consensus price target of $14.00, suggesting a potential upside of 73.91%. Given Trillium Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Trillium Therapeutics is more favorable than Grifols SA, Barcelona.
Insider & Institutional Ownership
22.5% of Grifols SA, Barcelona shares are owned by institutional investors. Comparatively, 45.5% of Trillium Therapeutics shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
This table compares Grifols SA, Barcelona and Trillium Therapeutics’ net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
|Grifols SA, Barcelona
Grifols SA, Barcelona pays an annual dividend of $0.28 per share and has a dividend yield of 1.1%. Trillium Therapeutics does not pay a dividend. Grifols SA, Barcelona pays out 30.1% of its earnings in the form of a dividend.
Volatility & Risk
Grifols SA, Barcelona has a beta of 1.05, indicating that its share price is 5% more volatile than the S&P 500. Comparatively, Trillium Therapeutics has a beta of 1.78, indicating that its share price is 78% more volatile than the S&P 500.
Grifols SA, Barcelona beats Trillium Therapeutics on 7 of the 12 factors compared between the two stocks.
Grifols SA, Barcelona Company Profile
Grifols, S.A., a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company specializes in providing infusion solutions, nutrition products, and medical devices for use in hospitals and clinics. It operates through four segments: Bioscience, Diagnostic, Hospital, and Raw Materials and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use, including the reception, analysis, quarantine, classification, fractionation, and purification of plasma; and sells and distributes end products. This segment offers plasma products, such as IVIG, Factor VIII, A1PI, and albumin; and intramuscular immunoglobulins, ATIII, Factor IX, and plasma thromboplastin components. The Diagnostic segment focuses on researching, developing, manufacturing, and marketing in vitro diagnostics products comprising analytical instruments, reagents, software, and related products for use in clinical and blood bank laboratories. This segment serves blood donation centers, clinical analysis laboratories, and hospital immunohematology services. The Hospital segment manufactures and installs products used by hospitals consisting of parenteral solutions, and enteral and parenteral nutritional fluids. The Raw Materials and Others segment sells intermediate biological products; and renders manufacturing services to third party companies. The company also offers engineering services. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves hospitals and clinics, group purchasing organizations, governments, and other distributors through sales representatives, marketing partners, and third-party distributors. Grifols, S.A. was founded in 1940 and is headquartered in Barcelona, Spain.
Trillium Therapeutics Company Profile
Trillium Therapeutics Inc., a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The companys lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies and solid tumors therapy. Its product candidates also include TTI-622, an IgG4 SIRPaFc protein for combination therapy; bromodomain inhibitor; and epidermal growth factor receptor antagonist, which are in preclinical development stage, as well as undisclosed immuno-oncology targets that are in the discovery Phase. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was founded in 2004 and is headquartered in Mississauga, Canada.
Receive News & Ratings for Grifols SA Barcelona Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols SA Barcelona and related companies with MarketBeat.com's FREE daily email newsletter.